30 closest matches · ranked by relevance
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Lymphoma, B-Cell · Lymphoma, Non-hodgkins
Primary: Percentage of Enrolled Participants Who Actually Get Treated — 76.9 percentage of participants
ALL · B Cell Lymphoma · Leukemia
Primary: Number of Participants Who Received Preparative Chemotherapy Followed by Cluster of Differentiation (CD)19-Chimeric Antigen Receptor (CAR): CD19 CAR T-cells With < Grade…
Non-Hodgkins Lymphoma (NHL) Patients, With CD19+B Cell Lymphomas
Primary: Number of Subjects With an Overall Response (i.e. Either Complete Response or Partial Response) Evaluated at Three Months Post Infusion. — 24; 1; 1 Participants
Hematopoietic/Lymphoid Cancer · Adult Acute Lymphoblastic Leukemia in Remission · B-cell Adult Acute Lymphoblastic Leukemia
Primary: Number of Participants With Adverse Events — 20 participants
Lymphoma, Non-Hodgkin · Leukemia, Lymphocytic, B Cell · B-Cell Lymphoma
Primary: Grades of Toxicity by Type of Toxicity — 2; 2; 1; 1 toxicities
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Lymphoma, Non-Hodgkin · Lymphoma, B-Cell · Chronic Lymphocytic Leukemia
Primary: Number of Adverse Events After CAR 20/19-T Cell Infusion — 7; 4; 22 Serious Adverse Events
Lymphoma, Large-Cell, Anaplastic · Enteropathy-Associated T-Cell Lymphoma · Lymphoma, Large B-Cell, Diffuse
Primary: Maximum Tolerated Dose of Anti-Tumor Necrosis Factor (TNF) Receptor Superfamily Member 8 (CD30) Chimeric Antigen Receptor (CAR) in Participants With Advanced…
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Non-Hodgkin Lymphoma · Hodgkin Disease
Primary: Summary of Adverse Events (AEs) — 9; 13; 7; 12 participants
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 6; 2; 2; 0 Participants
B Cell Leukemia · B Cell Lymphoma
Primary: Number of Subjects With Study Related Adverse Events. — 59 Participants
Mantle Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants
Refractory B-Lineage Leukemia · Relapsed B-Lineage Leukemia · Refractory B-Lineage Lymphoma
Primary: Phase I: Incidence of Any DLT Attributed to DT2219 in the First Cycle — 1; 3; 0 events
B-Lymphoid Malignancies · Acute Lymphocytic Leukemia · Chronic Lymphocytic Leukemia
Primary: Number of Events That Was Grade 3-4 Toxicities — 4; 1; 22; 1 events
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Patients With B Cell ALL, Relapsed or Refractory, With no Available Curative Treatment Options
Primary: Overall Complete Remission Rate at Day 28 After CART-19 Therapy — 8; 10; 6; 6 Participants
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Non-Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) as Determined by Local Investigator — 32.1 Percentage of participants
Lymphoma
Primary: Overall Response Rate as Assessed According to the"Revised Response Criteria for Malignant Lymphoma" (Cheson 2007). — 5; 2; 7; 1 Participants
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Lymphoma
Primary: Number of Participants With Absolute Neutrophil Count >= 500/Mcl for 3 Consecutive Measurements on Different Days and Platelet Count > 20,000/mm^3 With no Platelet…
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Lymphoma, Non-Hodgkin · Lymphoma, Nonhodgkin · Lymphoma, B-Cell
Primary: Overall Response Rate (ORR) — 80.3 Percent of Participants — p=<.0001
Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) — 46.2 percentage of participants — p=0.0044
Lymphoma, Non-Hodgkin
Primary: Overall Response Rate (ORR) Per Independent Review Committee in Cohorts 1, 2 and 3 — 61.1; 63.0; 70.0 Percent of Participants
Lymphoma, Non-Hodgkin
Primary: Event-free Survival (EFS) Per Independent Review Committee (IRC) — 2.4; 29.5 Months
Acute Lymphoblastic Leukemia
Primary: Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment. — 68.9 percentage of subjects
B-ALL · B-cell Non Hodgkin Lymphoma · DLBCL
Primary: Rate of Successful Manufacture of CD22 CAR T Cells — 94; 100; 100 Percentage